The Healing Power of Botanical Therapeutics®

The Healing Power of Botanical Therapeutics®

Company Contact:

Steve Haag

Investor Relations

(201) 647-3757

HERBORIUM TO HOLD SHAREHOLDER CONFERENCE CALL

Saddle Brook, NJ,

November 2, 2010 -- Herborium Group, Inc., (PK: HBRM) www.herborium.com, a Botanical Therapeutics™ company, today announced Dr. Agnes Olszewski, Herborium Group’s president and chief executive officer, will hold a shareholder conference call on Wednesday, November 3, 2010, at 4:15 PM EDT, to discuss its 2011 marketing plan and make an important announcement to shareholders.

“I look forward to speaking with Herborium’s friends and shareholders during this upcoming call, and sharing with them our immediate sales and marketing initiatives and distribution arrangements” commented Dr. Agnes P. Olszewski, Herborium Group’s president and chief executive officer. “We will discuss our new 2011 marketing plan, current product development initiatives, and the significant market opportunity afforded AcnEase® by the withdrawal of Roche’s Accutane®. I respectfully suggest that due to the dense subject matter, those who wish should be prepared to take notes.”

Shareholders can participate on Wednesday, November 3, 2010, by dialing (805) 309-0111 and entering access code 646614, up to 10 minutes before the call, beginning at 4:15 PM EDT, 3:15 PM CDT, 2:15 PM MDT, and 1:15 PM PDT.

Shareholder questions will be answered during the call; shareholders are encouraged to e-mail their questions for management to herborium@smallcapss.com, any time before of the call to ensure questions are covered in the time allowed.

About Herborium Group, Inc.

Herborium Group, Inc., a Botanical Therapeutics® company, focuses on developing, licensing, and marketing proprietary, botanically based medicinal products to consumers and healthcare professionals. The Company’s business model focuses on emerging market opportunities spearheaded by the growth of a new market sector located between high-cost, high-risk, ethical pharmaceuticals and commoditized classic nutraceuticals (supplements). The Company uses clinical validation and a proactive regulatory strategy based on the FDA Guidance for Industry: Botanical Drug Products (FDA Guidance 2004) to establish and maintain a differential advantage. For more information, please visit www.herborium.com and www.acnease.com.

One of our most important responsibilities is to communicate with shareholders in an open and direct manner. Comments are based on current management expectations, and are considered "forward-looking statements," generally preceded by words such as "plans," "expects," "believes," "anticipates," or "intends." We cannot promise future returns. Our statements reflect our best judgment at the time they are issued, and we disclaim any obligation to update or alter forward-looking statements as the result of new information or future events. The Company urges investors to review the risks and uncertainties contained within its filings with the OTC Markets and/or Securities and Exchange Commission.